Results 131 to 140 of about 792,108 (354)

Function of Connexins in the Interaction between Glial and Vascular Cells in the Central Nervous System and Related Neurological Diseases

Neural Plasticity, 2018
Neuronal signaling together with synapse activity in the central nervous system requires a precisely regulated microenvironment. Recently, the blood-brain barrier is considered as a “neuro-glia-vascular unit,” a structural and functional compound ...
Yinan Zhao, Yanguo Xin, Zhiyi He, Wenyu Hu   +3 more
doaj   +1 more source

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda, Masamitsu Takatama, Mikio Shoji   +13 more
wiley   +1 more source

Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy

, 2012
Blood–brain barrier dysfunction is implicated in various neurological conditions. Modulating the blood–brain barrier may have therapeutic value. Progress is hindered by our limited understanding of the pathophysiology of the blood–brain barrier in humans,
Martinian, L., Liu, J.Y.W., Figarella-Branger, D., Catarino, C.B., Koepp, M., Sisodiya, S.M., Bartolomei, F., Thom, M.   +7 more
core   +1 more source

Tissue plasminogen activator enhances the hypoxia/reoxygenation-induced impairment of the blood-brain barrier in a primary culture of rat brain endothelial cells. [PDF]

, 2008
Hemorrhagic transformation is a major complication associated with tissue plasminogen activator (tPA) therapy for ischemic stroke. We studied the effect of tPA on the blood-brain barrier (BBB) function with our in vitro monolayer model generated using ...
Nagata, Izumi, Tsutsumi, Keisuke, Suyama, Kazuhiko, Hayashi, Kentaro, Kawakubo, Junichi, Hiu, Takeshi, Kitagawa, Naoki, Niwa, Masami, Nakagawa, Sinsuke, Honda, Masaru   +9 more
core   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source

Blood–brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound

Nature Communications, 2018
Magnetic resonance-guided focused ultrasound in combination with intravenously injected microbubbles has been shown to transiently open the blood–brain barrier, and reduce beta-amyloid and tau pathology in animal models of Alzheimer’s disease.
N. Lipsman, Y. Meng, A. Bethune, Yuexi Huang, B. Lam, M. Masellis, N. Herrmann, C. Heyn, I. Aubert, A. Boutet, Gwenn S. Smith, K. Hynynen, S. Black   +12 more
semanticscholar   +1 more source

Quantitative PET imaging and modeling of molecular blood-brain barrier permeability

Nature Communications
Neuroimaging of blood-brain barrier permeability has been instrumental in identifying its broad involvement in neurological and systemic diseases. However, current methods evaluate the blood-brain barrier mainly as a structural barrier. Here we developed
Kevin J. Chung, Yasser G. Abdelhafez, Benjamin A. Spencer, Terry Jones, Quyen Tran, Lorenzo Nardo, Moon S. Chen, Souvik Sarkar, Valentina Medici, Victoria Lyo, Ramsey D. Badawi, Simon R. Cherry, Guobao Wang   +12 more
doaj   +1 more source

ALDOA Promotes Glycolysis and NLRP3/GSDMD Pyroptosis to Accelerate ALS Progression

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Amyotrophic lateral sclerosis (ALS) is characterized by progressive motor neuron degeneration. Glycolytic dysregulation is implicated in disease progression, yet the underlying mechanisms remain unclear. This study investigates how Aldolase A (ALDOA) drives ALS progression through glycolysis‐mediated motor neuron pyroptosis.
Kaixin Yan, Yan Jiang, Yuxuan Yong, Tianshuo Zhang, Niannian Zhang, Qianqian Zeng, Xue Gong, Li Meng, Fangfang Bi, Yongmin Liu   +9 more
wiley   +1 more source

The cerebrovascular effects of adrenaline, noradrenaline and dopamine infusions under propofol and isoflurane anaesthesia in sheep

, 2002
Publisher's copy made available with the permission of the publisher © Australian Society of AnaesthetistsInfusions of catecholamines are frequently administered to patients receiving propofol or isoflurane anaesthesia.
Grant, C., Upton, R., Martinez, A., Myburgh, J.   +3 more
core   +1 more source

An Induced Pluripotent Stem Cell-Derived Human Blood–Brain Barrier (BBB) Model to Test the Crossing by Adeno-Associated Virus (AAV) Vectors and Antisense Oligonucleotides

, 2023
The blood-brain barrier (BBB) is the specialised microvasculature system that shields the central nervous system (CNS) from potentially toxic agents. Attempts to develop therapeutic agents targeting the CNS have been hindered by the lack of predictive ...
Bowerman, Melissa, Malerba, Alberto, Selvakumaran, Jamuna, Yáñez-Muñoz, Rafael J, Lu-Nguyen, Ngoc, Wood, Matthew J, Ursu, Simona   +6 more
core   +1 more source